Monthly Prescribing Reference
   
Subscribe to our RSS feeds RSS | Login | Register
  • HOME
  • SPECIALTY
    • Hematology-Oncology
    • Long Term Care
    • Nurse Practitioners
    • OB/GYN
    • Pharmacists
    • Physician Assistants
    • Primary Care Physicians
    • Residents
    • Urologists
  • THERAPEUTIC CATEGORIES
  • BRAND
  • GENERIC
  • COMPARE
  • NEWS
    • Drug News
    • Drugs in the Pipeline
    • Drug Safety Alerts and Recalls
    • New Drug Products
    • Polls & Surveys
    • Newsletters
    • News from Haymarket Journals
  • RESOURCES
    • Alerts (Sponsored)
    • Clinical Charts
    • Common Medical Abbreviations
    • Company
    • Drug Monograph Format
    • FDA Orange Book
    • Pharmacology Notes
    • Professional Associations
    • Video
    • Blogs
    • MPR Publications
    • Customer Service
    • Online Banner Ad Specs
    • Subscribe
  • DOWNLOAD
  • CME
  • JOBS
  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
Home > Manufacturers > D > Dermik Laboratories

Dermik Laboratories

 

Address:

1050 Westlakes Drive
Berwyn, PA 19312

Email:

NA

Website:

click to visit

Phone:

(800) 633-1610

Fax:

NA

 
Compare | Add to Clipboard | View Clipboard
Name Section Compare
BENZACLIN
Dermatological Disorders > Acne
compare
BENZAGEL
Dermatological Disorders > Acne
compare
BENZAMYCIN
Dermatological Disorders > Acne
compare
BENZAMYCIN PAK
Dermatological Disorders > Acne
compare
CARAC
Dermatological Disorders > Miscellaneous dermatological conditions
compare
DERMATOP CREAM
Dermatological Disorders > Topical steroids
compare
DERMATOP OINTMENT
Dermatological Disorders > Topical steroids
compare
HYTONE
Dermatological Disorders > Topical steroids
compare
HYTONE 2.5%
Dermatological Disorders > Topical steroids
compare
KLARON
Dermatological Disorders > Acne
compare
NORITATE
Dermatological Disorders > Rosacea
compare
PENLAC
Dermatological Disorders > Skin infections (topicals)
compare
PSORCON e CREAM
Dermatological Disorders > Topical steroids
compare
PSORCON e OINTMENT
Dermatological Disorders > Topical steroids
compare
SULFACET-R
Dermatological Disorders > Acne
compare
Dermatological Disorders > Rosacea
compare
VANAMIDE
Dermatological Disorders > Pruritus and dry skin
compare
VYTONE
Dermatological Disorders > Topical steroids
compare
  • Most Popular
  • Most Emailed
  • Most Recent
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • Botox approved for upper limb spasticity
  • FDA halts marketing of unapproved nitroglycerin tablets
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • FDA warns of intravascular hemolysis risk with WinRho SDF
  • Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
  • Neosalus Cream available for dermatitis
  • FDA warns of reduced Plavix efficacy in poor metabolizers
  • Bowel Cleansers
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Recommended Adult Immunization Schedule
  • Prevnar 13 pneumococcal disease vaccine approved
  • Xiaflex available for Dupuytren's contracture
  • Hizentra approved for primary immunodeficiency
  • Kapidex to be marketed under new trade name Dexilant
  • Ampyra available for multiple sclerosis patients
  • FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia
  • FDA accepts NDA for JZP-6, a treatment for fibromyalgia
  • Rituxan approved for chronic lymphocytic leukemia
  • FDA halts marketing of unapproved nitroglycerin tablets
  • Hibiclens General Skin Cleansing Patient Kit available
  • Bowel Cleansers
  • Neosalus Cream available for dermatitis
  • FDA warns of reduced Plavix efficacy in poor metabolizers
  • Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • FDA warns of intravascular hemolysis risk with WinRho SDF
Sponsored Links

MPR SITEMAP


Search our Drug Database

Browse by Brand
Browse by Generic
Browse by Manufacturer
Browse by Therapeutic Category

News

News
Drug News
New Drug Products
Polls & Surveys
Newsletters

Clinical Charts

Clinical Charts

Resources

Resources
Pharmacology Notes
Alerts (Sponsored)

Therapeutic Categories

Allergic Disorders
Cardiovascular System
Central Nervous System
Dental
Dermatological Disorders
Diagnostic Agents
Ear Disorders
Endocrine System
Eye Disorders
Gastrointestinal Tract
Hematology
Immune System
Infections & Infestations
Musculoskeletal Disorders
Neoplasms
Nutrition
OB/GYN
Pain & Pyrexia
Poisoning & Drug Dependence
Respiratory Tract
Urogenital System

More

Customer Service
Subscribe
Advertise
About Us
Permissions
MPR Publications
Disclaimer
Subscribe to our RSS feeds RSS


Other Haymarket Medical Websites


Cortlandt Forum

Clinical Advisor

Renal and Urology News

JAAPA

myCME - Online CME

McKnights Long Term Care News

International

healthcare republic

MIMS (drug database)
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions